Ray,
Do you ever monitor the PD list (PIENO)? There were a few who had been a
part of the fetal implant studies. One that I remember for sure is Dr.
Charles Meyer (psychiatrist) Charlie had some bad dyskensias because of it.
I remember another couple who had the "placebo" surgery. I believe they
declined having the implants later when they were given the chance because
of the unpredictable outcomes.
Another person on the PD list is Jim Finn. He has done extremely well with
the "Pig cell" transplant he had done a couple years ago. His results have
been phenomenal.
Besides the age factor with the fetal cell transplants, I think the biggest
factor was the amount & area of placement of the fetal cells.
Take care,
David Meigs
[log in to unmask]
Meigs Family Webpage:
http://home.earthlink.net/~davidmeigs/index.html
----- Original Message -----
From: "Raymond Strand" <[log in to unmask]>
To: <[log in to unmask]>
Sent: Saturday, August 25, 2001 10:43 AM
Subject: PMID: transplantation -- Freed still at it
Hello list:
Stem cellsd have been at the forefront, but,
here is another example alternative cell transplant experimentation.
You will recall that the 3 year follow up study of fetal implants
by Freed indicated differences between age groups in how well
the implant survived. This study addresses that.
Freed is one of the authors.
I am curious about the details of "embryonic dopamine cell implantation".
Not stem cells, but, embryonic.
Ray
.......................................................
Ann Neurol 2001 Aug;50(2):181-7
Blinded positron emission tomography study of dopamine cell implantation for
Parkinson's disease.
Nakamura T, Dhawan V, Chaly T, Fukuda M, Ma Y, Breeze R, Greene P, Fahn S,
Freed
C, Eidelberg D.
Functional Brain Imaging Laboratory, North Shore-Long Island Jewish Research
Institute, Manhasset, NY 11030, USA.
We assessed nigrostriatal dopaminergic function in Parkinson's disease (PD)
patients undergoing a double-blind, placebo-controlled surgical trial of
embryonic dopamine cell implantation. Forty PD patients underwent positron
emission tomography (PET) imaging with [18F]fluorodopa (FDOPA) prior to
randomization to transplantation or placebo surgery. The 39 surviving
patients
were rescanned one year following surgery. Images were quantified by
investigators blinded to treatment status and clinical outcome. Following
unblinding, we determined the effects of treatment status and age on the
interval changes in FDOPA/PET signal. Blinded observers detected a
significant
increase in FDOPA uptake in the putamen of the group receiving implants
compared
to the placebo surgery patients (40.3%). Increases in putamen FDOPA uptake
were
similar in both younger (age < or = 60 years) and older (age > 60 years)
transplant recipients. Significant decrements in putamen uptake were
evident in
younger placebo-operated patients (-6.5%) but not in their older
counterparts.
Correlations between the PET changes and clinical outcome were significant
only
in the younger patient subgroup (r = 0.58). The findings suggest that
patient
age does not influence graft viability or development in the first
postoperative
year. However, host age may influence the time course of the downstream
functional changes that are needed for clinical benefit to occur.
PMID: 11506400 [PubMed - in process]
.......................................................
Ray Strand
Prairie Sky Design
-----------------( on the Edge of the Prairie Abyss )---------------
when the sky is clear
the ground is visible
49/dx PD 2 yrs/40? onset
----------------------------------------------------------------------
To sign-off Parkinsn send a message to: mailto:[log in to unmask]
In the body of the message put: signoff parkinsn
----------------------------------------------------------------------
To sign-off Parkinsn send a message to: mailto:[log in to unmask]
In the body of the message put: signoff parkinsn
